Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Suzhou Zelgen Biopharmaceuticals Co had a gross margin of 97.01% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Suzhou Zelgen Biopharmaceuticals Co Gross Margin % Related Terms
Suzhou Zelgen Biopharmaceuticals Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Zelgen Biopharmaceuticals Co Gross Margin % Chart
SHSE:688266 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Suzhou Zelgen Biopharmaceuticals Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzhou Zelgen Biopharmaceuticals Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Suzhou Zelgen Biopharmaceuticals Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Suzhou Zelgen Biopharmaceuticals Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) has a Gross Margin % of 97.01% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors. This is near median its historical median of 91.90. Over the past decade, Suzhou Zelgen Biopharmaceuticals Co's Gross Margin % has ranged from 20.50 to 99.90. According to the industry distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #57 out of 733 companies in the Biotechnology industry, placing it in the top 7.8%.
Is Suzhou Zelgen Biopharmaceuticals Co's Gross Margin % too high?
Suzhou Zelgen Biopharmaceuticals Co's current Gross Margin % of 97.01% is near median its 10-year median of 91.90. Over the past 10 years, this metric has ranged from a low of 20.50 to a high of 99.90. The Biotechnology industry median Gross Margin % is 60.91. Suzhou Zelgen Biopharmaceuticals Co's value of 97.01% is 59.3% above this industry median. Based on the distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #57 out of 733 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Suzhou Zelgen Biopharmaceuticals Co has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzhou Zelgen Biopharmaceuticals Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #57 out of 733 companies for Gross Margin %. This places Suzhou Zelgen Biopharmaceuticals Co in the top 8% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Suzhou Zelgen Biopharmaceuticals Co's value of 97.01% is 59.3% above this benchmark. Historically, Suzhou Zelgen Biopharmaceuticals Co's own Gross Margin % has ranged from 20.50 to 99.90 over the past decade. While the company's 10-year median is 91.90 vs. the industry median of 60.91, Suzhou Zelgen Biopharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzhou Zelgen Biopharmaceuticals Co's current Gross Margin % of 97.01% is 59.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Zelgen Biopharmaceuticals Co's current Gross Margin % is 97.01%, which is near median its own 10-year median of 91.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Zelgen Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥216.30, compared to a current price of ¥140.00 — trading 35.3% below its estimated fair value. The current Gross Margin % is 97.01%, which is near median its 10-year median of 91.90 and 59.3% above the Biotechnology industry median of 60.91. Suzhou Zelgen Biopharmaceuticals Co's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266), the current Gross Margin % is 97.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Overvalued in 2026?
Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥140.00 is trading 35.3% below its estimated GF Value™ of ¥216.30.
GuruFocus considers Suzhou Zelgen Biopharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for SHSE:688266:
Gross Margin %: 97.01% (near median its 10-year median of 91.90)
GF Value™: ¥216.30 vs. price of ¥140.00 (35.3% below fair value)
Industry Position: 59.3% above the Biotechnology median (#57 of 733)
No single metric tells the full story. See the SHSE:688266 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzhou Zelgen Biopharmaceuticals Co Business Description
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
67GF Score
Get the complete analysis for SHSE:688266
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688266 has been successfully added to your 
